

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

EAGLE PHARMACEUTICALS, INC.,

Plaintiff,

v.

SLAYBACK PHARMA LLC and AZURITY
PHARMACEUTICALS, INC.

Defendants.

C.A. No. 25-75-JLH

RULE 7.1 CORPORATE DISCLOSURE STATEMENT

Pursuant to Federal Rule of Civil Procedure 7.1, the undersigned counsel for Defendant Azurity Pharmaceuticals, Inc. makes the following disclosure:

Azurity Pharmaceuticals, Inc. is a wholly-owned subsidiary of CutisPharma Intermediate Holdings, Inc. and no publicly held corporation owns ten percent (10%) or more of its stock.

Dated: April 7, 2025

SMITH KATZENSTEIN & JENKINS LLP

/s/ Neal C. Belgam

Neal C. Belgam (No. 2721)

Daniel A. Taylor (No. 6934)

1000 West Street, Suite 1501

Wilmington, DE 19801

(302) 652-8400

dtaylor@skjlaw.com

nbelgam@skjlaw.com

*Attorneys for Defendant Slayback Pharma LLC
and Azurity Pharmaceuticals, Inc.*